Navigation Links
SemBioSys announces first quarter 2008 financial and operational results
Date:5/9/2008

ogress further along the commercialization path, the Company initiates partnership activities and augments its product candidate pipeline.

Net loss for the three-month period ended March 31, 2008 was $5,017,055 or $0.19 per share, compared to a net loss of $3,228,411 or $0.17 per share for the three-month period ended March 31, 2007.

As of March 31, 2008 the Company had cash and cash equivalents totaling $16,284,778 and a net positive working capital balance of $15,260,129 compared to $20,444,013 and $19,518,408, respectively, at December 31, 2007. Total long-term debt at March 31, 2008 was $1,930,962 compared with $1,389,047 at December 31, 2007.

As at March 31, 2008 the Company had 25,937,476 common shares outstanding, 4,322,000 warrants, and 1,282,429 options.

About SemBioSys Genetics Inc. (http://www.sembiosys.com)

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and agricultural biotechnology markets. More information is available and can be accessed at http://www.sembiosys.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking stat
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. SemBioSys receives milestone payments from AVAC Ltd.
2. SemBioSys initiates toxicology study for safflower-produced insulin
3. SemBioSys announces 2007 financial and operational results
4. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
5. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
6. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
7. SemBioSys signs option agreement for safflower-produced food ingredient
8. SemBioSys announces 2007 third quarter results
9. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
10. SemBioSys updates Apo AI development program
11. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SC (PRWEB) October 22, 2014 ... of its cardiovascular pharmacogenetics menu, which enables healthcare ... outcomes. With PCLS’s evidence-based results, healthcare providers ... and optimize their therapy, while minimizing risks for ... the U.S., according to the FDA [1] more ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... Diabetes Federation, approximately 400 million people worldwide are living ... 552 million people by 2030.  The global market for ... In 2012 approximately 330,000 people worldwide died from pancreatic ... of death due to cancer in the ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
(Date:10/20/2014)... , October 20, 2014 , ... (GI) disorders and the delivery of care has revealed ... and worrying inequalities in the provision of healthcare services ... was commissioned by United European Gastroenterology (UEG), have been ... and public awareness of the burden of GI disorders ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
... Technical Merit and Pricing Key Factors, ... Inc. today,announced that the company has been ... organization MedAssets Supply Chain Systems. The,extension agreement ... reagents, consumables and services effective October,1, 2007, ...
... Fla., Oct. 24 Nabi,Biopharmaceuticals (Nasdaq: NABI ... 2007, it commenced mailing its definitive proxy statement ... its biologics strategic,business unit and certain corporate shared ... subsidiary of Biotest AG,pursuant to an asset purchase ...
... JOLLA, Calif., Oct. 24 Immunosyn,Corporation,s (OTC Bulletin ... to brokers and financial institutions at the Financial,Services ... Mountain,Resort in Phoenix, AZ on Thursday, October 25, ... sales and,distribution rights to SF-1019 from its largest ...
Cached Biology Technology:Sysmex America Awarded MedAssets Supply Chain Systems Hematology Contract Extension 2Nabi Biopharmaceuticals Announces Mailing of Definitive Proxy Statement and Release Date of Third Quarter 2007 Financial Results 2Nabi Biopharmaceuticals Announces Mailing of Definitive Proxy Statement and Release Date of Third Quarter 2007 Financial Results 3Immunosyn Corporation to Present at FSX 2
(Date:10/17/2014)... the University of Copenhagen have shown for the first ... of Cystic fibrosis patients, giving them the opportunity to ... chronic infections. , The study also discovered the bacterial ... patients was halted or slowed down by the immune ... the oxygen and helped "suffocate" the bacteria, forcing the ...
(Date:10/16/2014)... the bowel lining develops and, in the process, suggested ... The researchers produced evidence that stem cells are responsible ... feature of the bowel lining, and believe these stem ... finding as scientists are still divided on the stem ... Wee Tan and Professor Tony Burgess from the Walter ...
(Date:10/15/2014)... WASHINGTON, N.Y. , Oct. 15, 2014 /PRNewswire/ ... technology solutions for home and community-based care, today ... benefits of implementing Sandata,s Santrax® Electronic Visit Verification™ ... Care Services is a home health company founded ... Texas . The ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... Tampa, Fla. (Dec, 19 2011) A ... into rats modeled with amyotrophic lateral sclerosis (ALS), ... lethal, neuromuscular disease, have tested four different immunosuppressive ... therapeutic effects. Their study demonstrated that a combined, ...
... that when people think about having children, men want ... lack of preference - is now a standard cultural ... says Lonnie Aarssen, a Queen,s biology professor and co-author ... gender bias, despite the researchers, prediction that they would ...
... of Chinese and Swedish researchers rediscovered the breeding area for ... Qinling mountains, Shaanxi province, north central China. Seven singing ... National Nature Reserves which almost equals the total number ... the late 19th century. Nearly all of the birds were ...
Cached Biology News:Grafting of human spinal stem cells into ALS rats best with immunosuppressant combination 2Sensational bird finding in China 2Sensational bird finding in China 3
... plus,for Reliable Sterile Filtration of Tissue Culture ... pump or tube pump, quickly and,reliably sterilize ... aqueous solutions. The combination of a ... de-aeration,ensures high flow rates and optimal total,throughputs. ...
... The EasyCount System is a fluorescent microscopy-based ... live nucleated cells and automatically calculates cell ... automating this routine function, the variability associated ... can be eliminated. Using the EasyCount ViaSure ...
... Adept CE 4100 high pressure pump ... precision, with software drive compensation, reducing pulsing ... are selectable in 0.001mL steps. , The ... and bio-compatible., Pumps may be programmed from ...
... paper sandwiches are composed of a precut ... thick filter paper that are preassembled into ... These 7 x 8.5 cm membrane sandwiches ... Gel-sized gels and are supplied as a ...
Biology Products: